The clinical efficacy of pemirolast potassium (Alegysal®) for perennial allergic rhinitis

Abstract

The clinical efficacy of pemirolast potassium (Alegysal®) was investigated in 29 patiets with perennial allergic rhinitis. The drug was orally administered for 4 weeks. All nasal symptoms improved in relation to the duration of the treatment period. The final global improvement of either “moderately improved” or greater was 41.4%. With respect to drug safety, one case complained of mild skin dryness as an adverse affect. The utility rate of “useful” or more was also 41.4%. The number of eosinophils observed in a nasal smear decreased after treatment, and the serum ECP levels also decreased after treatment in the improved cases. The changes in the nasal symptom score showed a good correlation with the clinical improvement based on ordinaly methods. According the these results, pemirolast potassium (Alegysal®) is thus considered to be useful for the treatment of perennial allergic rhinitis.